Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.3778
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
May 10, 2022
Via
Benzinga
Analyst Ratings for bluebird bio
May 10, 2022
Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
May 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
April 08, 2022
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.
Via
InvestorPlace
10 Biggest Price Target Changes For Wednesday
April 06, 2022
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.
Via
Benzinga
Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs
April 05, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 04, 2022
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
Expert Ratings For bluebird bio
April 06, 2022
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Via
Benzinga
55 Stocks Moving In Friday's Mid-Day Session
May 06, 2022
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Via
Benzinga
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
April 05, 2022
From
bluebird bio, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
March 15, 2022
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.
Via
Benzinga
bluebird bio's Return On Capital Employed Insights
March 10, 2022
According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $...
Via
Benzinga
76 Biggest Movers From Yesterday
March 08, 2022
Gainers Houston American Energy Corp. (NYSE: HUSA) surged 494.7% to close at $11.30 on Monday amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Niu Technologies Shares Plunge
March 07, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Monday. The Secretary of State Antony Blinken said on Sunday that the...
Via
Benzinga
Expert Ratings For bluebird bio
March 07, 2022
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Mid-Day Market Update: Nasdaq Drops 250 Points; Bed Bath & Beyond Shares Surge
March 07, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq dropping 250 points on Monday. The Secretary of State Antony Blinken said on Sunday that the United States and its...
Via
Benzinga
Why Bluebird Bio Shares Are Tumbling Today
March 07, 2022
Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of approximately $442 million....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
March 07, 2022
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics...
Via
Benzinga
46 Stocks Moving In Monday's Mid-Day Session
March 07, 2022
Gainers Houston American Energy Corp. (NYSE: HUSA) jumped 137.4% to $4.5150 amid continued momentum and an increase in the price of oil. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 07, 2022
Welcome back, trader! Let's get right into it with an overview of the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
A Peek Into The Markets: US Stock Futures Tumble; Crude Oil Jumps Over 7%
March 07, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade amid escalating Russia-Ukraine concerns. Investors are awaiting earnings results from Ciena Corporation...
Via
Benzinga
5 Stocks To Watch - Monday, Mar. 7
March 07, 2022
Some of the stocks that may grab investor focus today.
Via
Talk Markets
5 Stocks To Watch For March 7, 2022
March 07, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Ciena Corporation (NYSE: CIEN) to report quarterly earnings at $0.45 per share on revenue of $856...
Via
Benzinga
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies
January 18, 2022
The FDA has extended the review period for Bluebird bio Inc's (NASDAQ: BLUE) biologics licensing applications (BLA) for its lentiviral vector gene...
Via
Benzinga
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
January 18, 2022
From
bluebird bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference
January 11, 2022
Bluebird bio Inc (NASDAQ: BLUE) announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference, including 2022 program milestones and...
Via
Benzinga
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
From
bluebird bio, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.